Recent

% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

  • macrocosmonaut macrocosmonaut May 4, 2009 5:25 PM Flag

    Ampligen - best studied TLR activator

    >>The experimental therapeutic Ampligen(R) is perhaps the best studied TLR activator in human clinical trials to date, having been administered more than 75,000 times in approximately 15 clinical trials of which four were very well-controlled (placebo-controlled, randomized, multi-center, double-blinded).

    "These scientific findings go a long way toward explaining how a single, relatively simple compound, Ampligen(R), can repeatedly show therapeutic promise in such a broad array of indications. The findings may also have broad economic implications for the American biotechnology sector," commented Dr. William A. Carter, Chairman and CEO of Hemispherx Biopharama, Inc. "According to a recent KPMG Bioscience report, our sector recently achieved a new high of $70 billion in revenues a year, but is now faced with many very short product life cycles, large portfolios of expiring patents and the corresponding potential for global generic competition. However, specific TLR promoters, such as Ampligen(R), may have the potential to increase the efficacy of a broadly diverse set of previously licensed biological products, thus effectively extending their useful commercial life cycles." Hemispherx has a set of patent applications pending worldwide related to safely enhancing the therapeutic responses of biological products.<<

    M.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
HEB
0.121-0.008(-6.27%)3:12 PMEDT